Time filter

Source Type

Dmitriev A.A.,RAS Engelhardt Institute of Molecular Biology | Rosenberg E.E.,NASU Institute of Molecular Biology and Genetics | Krasnov G.S.,RAS Engelhardt Institute of Molecular Biology | Gerashchenko G.V.,NASU Institute of Molecular Biology and Genetics | And 15 more authors.
Disease Markers

A significant need for reliable and accurate cancer diagnostics and prognosis compels the search for novel biomarkers that would be able to discriminate between indolent and aggressive tumors at the early stages of disease. The aim of this work was identification of potential diagnostic biomarkers for characterization of different types of prostate tumors. NotI-microarrays with 180 clones associated with chromosome 3 genes/loci were applied to determine genetic and epigenetic alterations in 33 prostate tumors. For 88 clones, aberrations were detected in more than 10% of tumors. The major types of alterations were DNA methylation and/or deletions. Frequent methylation of the discovered loci was confirmed by bisulfite sequencing on selective sampling of genes: FGF12, GATA2, and LMCD1. Three genes (BHLHE40, BCL6, and ITGA9) were tested for expression level alterations using qPCR, and downregulation associated with hypermethylation was shown in the majority of tumors. Based on these data, we proposed the set of potential biomarkers for detection of prostate cancer and discrimination between prostate tumors with different malignancy and aggressiveness: BHLHE40, FOXP1, LOC285205, ITGA9, CTDSPL, FGF12, LOC440944/SETD5, VHL, CLCN2, OSBPL10/ZNF860, LMCD1, FAM19A4, CAND2, MAP4, KY, and LRRC58. Moreover, we probabilistically estimated putative functional relations between the genes within each set using the network enrichment analysis. © 2015 Alexey A. Dmitriev et al. Source

Davydov M.,Nn Blokhin Russian Cancer Research Center | Delektorskaya V.V.,Nn Blokhin Russian Cancer Research Center | Kuvshinov Y.P.,Nn Blokhin Russian Cancer Research Center | Lisovsky M.,Dartmouth Hitchcock Medical Center | And 4 more authors.
Annals of the New York Academy of Sciences

The following, from the 12th OESO World Conference: Cancers of the Esophagus, includes commentaries on the evolution of Barrett's dysplasia to early cancer; the early detection of esophageal cancer in China; new technologies of treatment for dysplasia; the prognostic value of molecular markers expression in esophageal squamous cell carcinoma; the follow-up schedule after ablation of high-grade dysplasia; intramucosal cancers; and tubular widespread endoscopic esophageal submucosal dissection with high-dose steroid stricture prevention. © 2014 New York Academy of Sciences. Source

Filonenko E.,Pa Herzen Moscow Cancer Research Institute | Kaprin A.,Pa Herzen Moscow Cancer Research Institute | Alekseev B.,Pa Herzen Moscow Cancer Research Institute | Urlova A.,Pa Herzen Moscow Cancer Research Institute
BioMed Research International

Penile cancer is a rare pathology. For penile cancer surgical treatment, radiotherapy, chemotherapy, and combined modality treatment are available. Because of great importance of this organ for mental condition of patient, the development of organ-preserving methods allowing to minimize impact on patient's quality of life without compromising of oncological results is desirable. In the Center of Laser and Photodynamic diagnosis and treatment of tumors in P.A. Herzen Moscow Cancer Research Institute the methods of photodynamic therapy in patients with penile cancer have been developed. From 2011 to 2013 the treatment was conducted in 11 patients with precancer and cancer of penile. The average age was 56.6. According to morphological diagnosis photodynamic therapy (PDT) was performed using two methods. One method included topical application of agent for PDT and the second intravenous administration of photosensitizer. For topical application alasens was used and for intravenous injection we applied radachlorine. All patients had no complications. Complete regression was achieved in 9 patients, and partial regression in 2. Thus, the results showed that photodynamic therapy for penile cancer stage Tis-1N0M0 permits performing organ-preserving treatment with satisfactory oncological results and no impairment of patient's quality of life. Copyright © 2015 Elena Filonenko et al. Source

Discover hidden collaborations